NASDAQ:CNAT - Conatus Pharmaceuticals Inc.
$0.83
 $0.12
+17.02%
4:00PM EDT
2019-04-18
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CNAT     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 81   199. 07   233. 87  
42 stocks rank:  3. 52 K 1. 43 K 1. 06 K
# analyst opinions:  2. 00   14. 48   14. 09  
mean recommendation:  3. 00   2. 09   2. 01  

quick ratio:  2. 40   5. 29   1. 92  
current ratio:  2. 56   5. 64   2. 40  

target price low:  1. 50   84. 50   115. 74  
target price avg:  1. 60   110. 73   137. 39  
target price high:  1. 70   136. 41   157. 80  
1-yr high:  6. 49   114. 11   138. 85  
last close:  0. 83   87. 56   116. 78  
50-day avg:  1. 79   95. 43   123. 53  
200-day avg:  3. 35   94. 13   121. 20  
1-yr low:  0. 71   72. 67   98. 41  
volume:  1. 25 M 2. 43 M 4. 85 M
50-day avg volume:  1. 22 M 2. 72 M 4. 97 M
200-day avg volume:  805. 76 K 2. 90 M 4. 58 M

1-day return:  16. 90 % -0. 40 % 0. 07 %
this week return:  -31. 97 % -5. 72 % -4. 11 %
12-wk return:  -53. 37 % 1. 78 % -0. 04 %
52-wk return:  -66. 04 % 10. 81 % 14. 09 %

enterprise value (EV):  3. 42 M 51. 19 B 117. 96 B
market cap:  27. 56 M 43. 00 B 104. 52 B
EBITDA:  -18. 19 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 19   4. 34   13. 27  
enterprise/revenue (EV/R):  0. 10   68. 16   13. 68  
total revenue:  33. 59 M 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -18. 01 M 2. 20 B 4. 21 B

shares outstanding:  33. 17 M 570. 91 M 1. 24 B
shares:  29. 85 M 571. 02 M 1. 23 B
shares short:  3. 05 M 9. 93 M 16. 79 M
shares short prior month:  3. 27 M 9. 96 M 16. 58 M
short ratio:  3. 15   5. 31   3. 30  
short % of float:  10. 67 % 5. 81 % 2. 61 %
total cash/share:  1. 23   11. 13   9. 30  
total cash:  40. 69 M 6. 70 B 7. 10 B
free cash flow:  -20. 06 M 3. 58 B 4. 74 B
operating cash flow:  -34. 86 M 4. 14 B 6. 32 B

book value:  0. 83   12. 76   26. 84  
price/book:  1. 00   3. 08   -1. 74  
gross profits:  33. 59 M 8. 03 B 34. 77 B
operating margins:  -54. 42 % -721. 97 % -88. 82 %
EBITDA margins:  -54. 15 % 10. 94 % 22. 54 %
profit margins:  -53. 62 % 7. 81 % 10. 60 %
gross margins:  -23. 17 % 37. 02 % 55. 68 %

1-yr max volatility:  -56. 89 % --- ---
1-yr mean volatility:  -0. 17 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 59   2. 39   4. 08  
forward EPS:  -0. 52   3. 97   7. 14  
P/E:  -1. 40   13. 59   22. 83  
forward P/E:  -2. 35   -20. 05   14. 49  
PE/G:  0. 09   -1. 46   1. 68  
growth:  -15. 90 % 126. 81 % 29. 29 %
earnings high:  -0. 07   1. 02   1. 63  
earnings avg:  -0. 12   0. 76   1. 51  
earnings low:  -0. 16   0. 47   1. 39  
revenue high:  8. 79 M 2. 68 B 10. 71 B
revenue avg:  8. 26 M 2. 59 B 10. 49 B
revenue low:  7. 50 M 2. 49 B 10. 25 B
return on assets:  -17. 47 % -2. 80 % 5. 29 %
return on equity:  -65. 02 % -18. 52 % 7. 38 %
revenue growth:  -15. 90 % 92. 55 % 19. 15 %
revenue/share:  1. 11   13. 27   55. 24  

beta (1yr vs S&P500):  2. 77   1. 24   0. 93  
sharpe (1yr):  -0. 34   0. 29   0. 60  

held % insiders:  3. 34 % 6. 38 % 3. 38 %
held % institutions:  24. 84 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CNAT
.    + 0.318 =         0.318 :: INITIAL WEIGHT
.   + 38.152 =         38.47 :: spline projection addition
.    x 1.432 =         55.09 :: industry recommendation factor
.    x 1.063 =        58.561 :: symbol recommendation factor
.    x 1.001 =        58.648 :: EV/R factor
.    x 0.998 =        58.546 :: return on assets factor
.    x 0.993 =        58.165 :: return on equity factor
.    x 0.998 =        58.073 :: revenue growth factor
.    x 2.454 =       142.522 :: current ratio factor
.     x 1.31 =       186.716 :: quick ratio factor
.    x 1.148 =       214.314 :: short ratio factor
.     x 2.01 =       430.782 :: price-to-book factor
.    x 2.154 =       927.713 :: P/E weight
.    x 1.836 =      1703.167 :: PE/G factor
.    x 1.157 =      1970.564 :: beta factor
.    x 0.339 =       668.772 :: sharpe factor
.    x 1.992 =      1331.969 :: target low factor
.    x 1.321 =       1759.61 :: target mean factor
.    x 1.102 =      1939.762 :: target high factor
.    x 1.312 =      2544.285 :: industry 2-weeks return factor
.    x 0.582 =      1480.923 :: "drift" penalty 2 days ago
.    x 0.848 =      1256.414 :: "drift" penalty 4 days ago
.    x 0.905 =      1136.633 :: "drift" penalty 5 days ago
.    x 0.397 =       451.603 :: overall "drift" factor
.    x 0.998 =       450.528 :: largest single-day jump factor
.    x 0.061 =        27.555 :: low price factor
.      x 1.0 =        27.551 :: factor hist industry gain for week 15
.   cubeRoot =          3.02 :: reduced to standardize
.   - 30.659 =         0.806 :: add/subtract for performance
.                      0.806 :: FINAL WEIGHT for NASDAQ:CNAT


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org